A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma

Highlights

- The TORKi MLN0128 shows poor residence time, underlying poor in vivo efficacy
- RapaLink-1 shows improved potency compared with rapamycin and MLN0128
- RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1
- RapaLink-1 crosses the blood-brain barrier, blocking three brain cancer models in vivo

Authors

QiWen Fan, Ozlem Aksoy, Robyn A. Wong, ..., Masanori Okaniwa, Kevan M. Shokat, William A. Weiss

Correspondence

waweiss@gmail.com

In Brief

Fan et al. target mTORC1 activity in glioblastoma (GBM) with RapaLink-1, which is comprised of rapamycin linked to an mTOR kinase inhibitor. RapaLink-1 decreases mTORC1 activity in the brain and suppresses the growth of GBM xenografts and a genetically engineered mouse model of brain cancer in vivo.
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma

QiWen Fan,1,3 Ozlem Aksoy,1,3 Robyn A. Wong,1,3 Shirin Ilkhanizadeh,1,3 Chris J. Novotny,2 William C. Gustafson,3,4 Albert Yi-Que Truong,4,5 Geraldine Cayanan,1,3 Erin F. Simonds,1,3 Daphne Haas-Kogan,6 Joanna J. Phillips,3,6 Theodore Nicolaides,3,5 Masanori Okaniwa,2 Kevan M. Shokat,2 and William A. Weiss1,3,4,5,*

1Department of Neurology
2Howard Hughes Medical Institute, Department of Cellular and Molecular Pharmacology
University of California, San Francisco, CA 94158, USA
3Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94158, USA
4Department of Pediatrics, University of California, San Francisco, CA 94158, USA
5Department of Neurological Surgery, University of California, San Francisco, CA 94158, USA
6Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
*Correspondence: waweiss@gmail.com
http://dx.doi.org/10.1016/j.ccell.2017.01.014

SUMMARY

Although signaling from phosphatidylinositol 3-kinase (PI3K) and AKT to mechanistic target of rapamycin (mTOR) is prominently dysregulated in high-grade glial brain tumors, blockade of PI3K or AKT minimally affects downstream mTOR activity in glioma. Allosteric mTOR inhibitors, such as rapamycin, incompletely block mTORC1 compared with mTOR kinase inhibitors (TORKi). Here, we compared RapaLink-1, a TORKi linked to rapamycin, with earlier-generation mTOR inhibitors. Compared with rapamycin and Rapalink-1, TORKi showed poor durability. RapaLink-1 associated with FKBP12, an abundant mTOR-interacting protein, enabling accumulation of RapaLink-1. RapaLink-1 showed better efficacy than rapamycin or TORKi, potently blocking cancer-derived, activating mutants of mTOR. Our study re-establishes mTOR as a central target in glioma and traces the failure of existing drugs to incomplete/nondurable inhibition of mTORC1.

INTRODUCTION

Glioblastoma (GBM), the most common primary brain tumor, represents one of the most aggressive cancers (Omuro and DeAngelis, 2013). Although signaling from phosphatidylinositol 3-kinase (PI3K) and AKT to mechanistic target of rapamycin (mTOR) is commonly dysregulated in GBM (Brennan et al., 2013), blockade of these upstream targets minimally affects mTOR activity in glioma (Fan et al., 2009). Direct targeting using allosteric inhibitors incompletely blocks mTORC1 activity (Feldman et al., 2009; Garcia-Martinez et al., 2009; Thoreen et al., 2009), while mTOR kinase inhibitors (TORKi) have not yet been fully evaluated in GBM.

mTOR exists in two distinct complexes, mTORC1 and mTORC2 (Loewith et al., 2002). With a half maximal inhibitory concentration for mTORC1 inhibition in the high picomolar range, clinically approved first-generation mTOR inhibitors rapamycin and rapalogs sensitively and specifically inhibit mTORC1 through binding to the FK506 rapamycin binding (FRB) domain of mTOR with the aid of FK506 binding protein 12 (FKBP12) (Chiu et al., 1994; Loewith et al., 2002). Importantly, the FRB domain of mTOR is exposed in the mTORC1 but not the mTORC2 complex, which confers the mTORC1 specificity of rapalogs (Gaubitz et al., 2015). Second-generation TORKi act through orthosteric interactions with the ATP binding pocket of mTOR kinase (Feldman et al., 2009; Garcia-Martinez et al., 2009; Thoreen et al., 2009). As a result, TORKi blocks activation of substrates of mTORC1 and mTORC2, whereas rapalogs only impact mTORC1 (Feldman et al., 2009; Garcia-Martinez et al., 2009; Hsieh et al., 2012; Thoreen et al., 2009).

Significance

Glioblastoma (GBM), the most common primary brain tumor, numbers among the most aggressive of cancers. Dysregulated PI3K, AKT, and mTOR signaling is found in a majority of tumors; however, blockade of PI3K and AKT, which signal upstream of mTOR, fails to impact mTOR activity in GBM. We compared the first-generation allosteric mTOR inhibitor rapamycin and second-generation TORKi in vivo. Neither substantially impacted GBM. To improve upon earlier-generation inhibitors, we next tested a TORKi targeted specifically to mTORC1. RapaLink-1 drove regression of intracranial brain cancers in vivo, improving survival compared with earlier-generation inhibitors.
Recently developed mTORC1-directed inhibitors combine the high affinity of rapamycin for mTORC1 with the effective kinase inhibition of the TORKi MLN0128 (Rodrik-Outmezguine et al., 2016). The linker portion of this third-generation mTOR inhibitor lies in a channel in the mTORC1 complex, in a manner that does not disrupt linked rapamycin binding to FKBP12 or the FRB domain of mTOR. These inhibitors thus leverage the high selectivity and affinity of rapamycin for mTORC1 to specifically “deliver” MLN0128 to the ATP site of mTOR mainly in the mTORC1 complex.

RESULTS

tOR Is a Central Therapeutic Target in GBM

To clarify the importance of mTOR as a target in GBM, we assessed proliferation (Figure 1A), cell cycle (Figure 1B), phosphatidylinositol 3,4,5-trisphosphate (PIP3) levels (Figure 1C), and activation of AKT, RPS6, and 4EBP1 (Figures 1D and S1) following treatment of LN229 cells with inhibitors targeting individual class I PI3Ks, a pan-inhibitor of class I PI3Ks, an inhibitor of AKT, an inhibitor of mTORC1, a TORKi, and a dual inhibitor of PI3K and mTOR. Decreased proliferation (Figure 1A) and arrest in G0/G1 (Figure 1B) correlated with blockade of mTORC1, as assessed by decreased p-RPS6S235/236 and p-4EBP1T37/46 (Figures 1D and S1). No correlation to proliferation was evident with the abundance of PIP3 or mTORC2 inhibition, as assessed by p-AKTS473 (Figures 1C and 1D). Only the abundance of AKT, an inhibitor of mTORC1, a TORKi, and a dual inhibitor of PI3K and mTOR. Decreased proliferation (Figure 1A) and arrest in G0/G1 (Figure 1B) correlated with blockade of mTORC1, as assessed by decreased p-RPS6S235/236 and p-4EBP1T37/46 (Figures 1D and S1). No correlation to proliferation was evident with the abundance of PIP3 or mTORC2 inhibition, as assessed by p-AKTS473 (Figures 1C and 1D). Only the abundance of PI3Kα induced modest blockade of proliferation and G1 arrest, while an inhibitor of PI3Kβ induced modest proliferative blockade without G1 arrest. Agents that blocked other class I PI3Ks reduced levels of the PIP3, but failed to affect proliferation or arrest at G1 (Figures 1A–1C). The allosteric mTOR inhibitor rapamycin reduced p-RPS6S235/236 but not p-4EBP1T37/46, which led to increased levels of PIP3 and p-AKT5473, and minimally affected proliferation. In contrast, the TORKi KU-0063794 (Garcia-Martinez et al., 2009) showed dose-dependent reduction of p-RPS6S235/236, p-4EBP1T37/46, and p-AKT5473, with a corresponding blockade of proliferation. Similar to rapamycin, KU-0063794 increased levels of PIP3, in accordance with a well-established mTORC1-negative feedback loop leading to reactivation of PI3K signaling (Sun et al., 2005). The pan-class I PI3K inhibitor GDC-0941 (Folkes et al., 2008) and the PI3K/mTOR inhibitor BEZ235 elicited cellular effects solely at doses sufficient to block mTOR directly (Figures 1A–1D). Data in Figures 1 and S1 suggest that blockade of mTORC1 was critical, whereas blockade...
of mTORC2 was dispensable for the anti-proliferative activity of PI3K and mTOR inhibitors in GBM, and reaffirm the importance of the mTORC1 target p-4EBP1 in the robust anti-proliferative activity of MLN0128 and rapamycin.

Rapalink-1 Is More Potent than First- and Second-Generation mTOR Inhibitors

We next tested Rapalink-1 and Rapalink-2, two different third-generation mTOR inhibitors that link MLN0128 to rapamycin but differ in linker lengths (Figure S2A). Rapalink-1 more potently reduced levels of both p-4EBP1 and proliferation, as compared with Rapalink-2 (Figures 2A, 2B, S2B, and S2C). We compared rapamycin, Rapalink-1, and MLN0128 in LN229 and U87MG. Both growth inhibition and arrest in G0/G1 were more potent in response to Rapalink-1, compared with rapamycin or MLN0128. Rapamycin only inhibited the mTORC1 target p-RPS6S235/236 (Figures 2A and S2E). MLN0128, in contrast, inhibited the mTORC1 targets p-RPS6S235/236 and p-4EBP1T37/46, as well as mTORC2 targets p-AKT$_{S473}$, p-SGK1$_{S78}$, and p-NDRG1T1346, and the p-AKT$_{S473}$ target p-GSK3B in a dose-dependent manner. Rapalink-1 selectively inhibited p-RPS6S235/236 and p-4EBP1T37/46 at doses as low as 1.56 nM. The mTORC2 targets p-AKT$_{S473}$, p-SGK1$_{S78}$, and p-NDRG1T1346, and the p-AKT$_{S473}$ target p-GSK3 in vivo (Figure 3A). RapaLink-1 was able to inhibit p-RPS6S235/236 and p-4EBP1T37/46 in a dose-dependent manner in brain, but it did not inhibit the mTORC2 substrate p-AKT$_{S473}$ in vivo (Figure 3A).

Having confirmed that Rapalink-1 inhibits mTORC1 activity in the brain, we next established intracranial xenografts, and the mice were treated with daily i.p. injections of MLN0128 or rapamycin every 5 or 7 days with Rapalink-1. We assessed tumor burden (Figures 3B and 3C), mTOR signaling (Figure 3D), and survival (Figure 3E). Rapalink-1 led to initial regression and subsequent stabilization of tumor size, while tumors treated with vehicle, rapamycin, or MLN0128 grew steadily (Figures 3B and 3C). Western blotting analysis of treated tumors demonstrated that Rapalink-1 efficiently blocked p-4EBP1T37/46, whereas MLN0128 and rapamycin only modestly blocked p-4EBP1T37/46 (Figure 3D). All treatments blocked p-RPS6S235/236, while MLN0128 uniquely inhibited p-AKT$_{S473}$. We followed mice on therapy for 14 weeks. Rapalink-1 was well tolerated and associated with significantly improved survival (p = 0.0238, vehicle versus MLN0128; p = 0.0011, vehicle versus rapamycin; p < 0.0001, vehicle versus Rapalink-1, log rank analysis; n = 9 mice per group) (Figure 3E). Treated tumors showed decreased proliferation in response to Rapalink-1 but were only modestly affected by earlier-generation inhibitors of mTOR (Figures 3F and 3G).

To extend these data, we next compared Rapalink-1, MLN0128, and rapamycin in a patient-derived GBM xenograft, GBM43 (Sarkaria et al., 2006), again assaying tumor burden and survival. Since rapamycin showed some efficacy in vivo at 1.5 mg/kg (Figure 3), we increased the dose to 5 mg/kg, close to the maximum tolerated dose (Houghton et al., 2010). We again established intracranial xenografts and treated with daily i.p. injections of MLN0128 or rapamycin every 5 days with Rapalink-1. Tumors treated with Rapalink-1 showed decreased tumor growth as assessed by luciferase signal compared with tumors treated with vehicle, rapamycin, or MLN0128 (Figures 4A and 4B). Western blotting of treated tumors isolates demonstrated that Rapalink-1 efficiently blocked p-4EBP1T37/46, whereas both MLN0128 and rapamycin only modestly blocked p-4EBP1T37/46. All treatments blocked p-RPS6S235/236, and MLN0128 again uniquely inhibited...
p-AKT 

We followed mice on therapy for 43 days. RapaLink-1 was well tolerated and associated with significantly improved survival (p = 0.0120, vehicle versus MLN0128; p = 0.0015, vehicle versus rapamycin; p = 0.0002, vehicle versus RapaLink-1; log rank analysis; n = 7 mice per group) (Figures 4D and 4E). Treated tumors showed decreased proliferation in response to RapaLink-1, and again were only modestly affected by earlier-generation inhibitors of mTOR (Figures 4F and 4G).

Because intracranial injection of GBM cells may disrupt the blood-brain barrier, we also tested the effects of RapaLink-1 on tumor burden in a genetically engineered “GTML” model in which medulloblastoma tumors arise spontaneously without mechanical disruption of the barrier and in which luciferase is driven as a transgene (Swartling et al., 2010). GTML mice were treated by i.p. injections of vehicle or RapaLink-1 (1.5 mg/kg, every 5 days). RapaLink-1 again showed clear anti-tumor efficacy in these barrier-intact mice, blocking both p-RPS6S235/236 and p-4EBP1T37/46 (Figures 4H–4J).

**RapaLink-1 Durably Blocks mTORC1**

FKBP12 is an abundant cellular protein (MacMillan, 2013), and it is expressed at high levels in human GBMs (Figure S4A).
Figure 3. Comparative Efficacy of MLN0128, RapaLink-1, and Rapamycin in Orthotopic GBM Xenografts

(A) BALB/c nu/nu mice were treated with i.p. injections of vehicle, MLN0128 (16 mg/kg), RapaLink-1 (0.4 or 4 mg/kg) or rapamycin (1.5 mg/kg) for 15 min, followed by i.p. injection of 250 mU insulin or saline for 15 min. Mice were euthanized, and skeletal muscle, liver, and brain were harvested, lysed, and analyzed by western blotting as indicated.

(B) U87MG cells expressing firefly luciferase were injected intracranially into BALB/c nu/nu mice. After tumor establishment, mice were sorted into four groups and treated by i.p. injections of vehicle (daily), MLN0128 (1.5 mg/kg, daily), RapaLink-1 (1.5 mg/kg, every 5 or 7 days), or rapamycin (1.5 mg/kg, daily). Bioluminescence imaging of tumor-bearing mice was obtained at days shown (day 0 was start of treatment), using identical imaging conditions.

(C) Dynamic measurements of bioluminescence intensity (BLI) in treated tumors over time. Regions of interest from displayed images were revealed on the tumor site and quantified as maximum photons/s/cm² squared/steradian. Data shown represent mean of photon flux ± SD from n = 12 mice. *p < 0.05, vehicle versus rapamycin; **p < 0.01, vehicle versus RapaLink-1; n.s., not significant, vehicle versus MLN0128 (two-tailed Student’s t test on day 25).

(D) Animals were euthanized when showing signs of illness, per IACUC protocol. Thirty min prior to being euthanized, three animals from each group treated as in (B) were injected with vehicle, MLN0128 (1.5 mg/kg), RapaLink-1 (1.5 mg/kg), or rapamycin (1.5 mg/kg). Tumors were harvested, lysed, and analyzed by western blotting as indicated.

(E) Survival curves of BALB/c nu/nu mice injected intracranially with U87MG cells. Five days after tumor implantation, mice were treated by i.p. injection of vehicle (daily), MLN0128 (1.5 mg/kg, daily) for 46 days, RapaLink-1 (1.5 mg/kg, every 5 days for 25 days, then once a week for 11 weeks), or rapamycin (1.5 mg/kg, daily). p = 0.0238, vehicle versus MLN0128; p = 0.0011, vehicle versus rapamycin; p < 0.0001, vehicle versus RapaLink-1, log rank analysis; n = 9 mice per group.

(F) Three animals from each group were euthanized on day 25. Samples were stained with H&E, and proliferating tumors cells were identified by immunohistochemistry for Ki67. Panel shows representative images. Scale bars, 100 µm.

(G) Data shown represent mean ± SD of five high-power microscopic fields from each of three tumors in each group. n.s., not significant; ***p < 0.001 by two-tailed Student’s t test. See also Figure S3.
Figure 4. Comparative Efficacy of MLN0128, RapaLink-1, and Rapamycin in an Orthotopic Patient-Derived Xenograft and Genetically Engineered Models

(A) GBM43 cells (1 × 10⁵) expressing firefly luciferase were injected intracranially in BALB/c nu/nu mice. After tumor establishment, mice were sorted into groups, and treated by i.p. injections of vehicle (daily), MLN0128 (1.5 mg/kg, daily), RapaLink-1 (1.5 mg/kg, every 5 days), or rapamycin (5 mg/kg, daily). Bioluminescence imaging of tumor-bearing mice was obtained at days 0, 3, 7, 10, and 14 (after starting treatment) using identical imaging conditions.

(B) Dynamic measurements of bioluminescence intensity (BLI) in treated tumors from (A). Regions of interest from displayed images were revealed on the tumor sites and quantified as maximum photons/s/cm²/steradian. Data shown are mean ± SD of n = 10 mice in each group. *p = 0.0254, vehicle versus MLN0128; *p = 0.0145, vehicle versus RapaLink-1 (two-tailed Student’s t test on day 14).

(C) Animals were euthanized when showing signs of illness, as per IACUC protocol. Three animals from each group treated as in (A) (daily for rapamycin and MLN0128, and every 5 days for RapaLink-1) were injected with vehicle, MLN0128 (1.5 mg/kg), RapaLink-1 (1.5 mg/kg), or rapamycin (5 mg/kg) 30 min prior to being euthanized. Tumors were harvested, lysed, and analyzed by western blotting as indicated.

(D) Body weights of mice in (A) were measured every 3 days for 12 days. Data shown are mean ± SD from n = 10 mice in each group.

(E) Survival curves of BALB/c nu/nu mice injected intracranially with GBM43 cells. Three days after tumor implantation, mice were treated by i.p. injection of vehicle (daily), MLN0128 (1.5 mg/kg, daily), RapaLink-1 (1.5 mg/kg, every 5 days), or rapamycin (5 mg/kg, daily). p = 0.0120, vehicle versus MLN0128; p = 0.0015, vehicle versus rapamycin; p = 0.0002, vehicle versus rapamycin; p = 0.0002, vehicle versus RapaLink-1; log rank analysis; n = 7 mice per group.
affinity of rapamycin for FKBP12 leads to accumulation of rapamycin in cells (Choi et al., 1996), resulting in durable blockade of p-RPS6S235/236. Having observed increased in vivo potency of RapaLink-1 compared with both rapamycin and MLN0128, we therefore examined whether the proposed binding of RapaLink-1 to FKBP12 might lead to durable mTORC1 inhibition in human glioma cells. We treated LN229 and U87MG cells with RapaLink-1 for 1 day followed by washout, assessing relative growth and signaling (Figures 5A, 5B, and S4B–S4D). Proliferation was blocked for days, with recovery starting between days 2 and 4 (Figures 5A and S4C). RapaLink-1 inhibited phosphorylation of RPS6 and 4EBP1 in a time-dependent manner, with persistent target inhibition over 24 hr, and some recovery by 48 hr (Figures 5B and S4D). In contrast, recovery of proliferation in cells treated with MLN0128 started after 1 day (Figures 5A and S5C), and recovery of signaling was observed at 1 hr after washout (Figures 5B and S4D). Rapamycin durably blocked p-RPS6S235/236 but not p-4EBP1T37/46, with minimal anti-proliferative activity in the GBM lines tested (Figures S5A, 5B, and S4B–S4D).

The immunosuppressive FK-506 does not inhibit mTORC1, but it competes with rapamycin for FKBP12 binding. Since FK-506 can block the effects of rapamycin (Shimobayashi and Hall, 2014), we next assessed how FK-506 or rapamycin affected growth inhibition or signaling changes in response to RapaLink-1 (Figures 5C, 5D, and S4E–S4G). Under conditions of excess FK-506 or rapamycin during the washout, recovery of signaling and proliferation were slightly improved (Figures 5C, 5D, S4F, and S4G). FK-506 by itself had little effect on either signaling or proliferation (Figures 5D and S4E). Consistent with the binding to FKBP12 leading to intracellular accumulation of RapaLink-1 over time, RapaLink-1 treatment of therapy-resistant LN229 and U87MG cells transduced with EGFRVIII (Nagane et al., 1998) decreased steadily over 72 hr (Figure 5E), correlating with a time-dependent decrease in p-RPS6S235/236 and p-4EBP1T37/46 (Figure 5F). Treatment with RapaLink-1 had no cytotoxic effect (Figure 5G). Thus, rapamycin is a durable inhibitor, but inefficiently blocks p-4EBP1T37/46. MLN0128 efficiently inhibits p-4EBP1T37/46, but shows short residence time. RapaLink-1 both durably and efficiently blocks p-4EBP1T37/46.

**FKBP12 Is Required for RapaLink-1 Activity**

If RapaLink-1 and rapamycin both require binding to FKBP12 for activity, then rapamycin should be able to block the anti-proliferative activity of RapaLink-1 (Figure 6A). Addition of rapamycin to RapaLink-1 led to a decrease in the anti-proliferative dose response to RapaLink-1 at intermediate doses (Figure 6B), associated with increased levels of p-4EBP1T37/46 (Figure 6C). In comparison, addition of rapamycin to MLN0128 did not affect the anti-proliferative dose response or levels of p-4EBP1T37/46 (Figures 5D and 6E). To test whether FK-506 also competes with RapaLink-1, we treated GBM cells with mTOR inhibitors alone or in combination with FK-506. FK-506 antagonized the inhibitory effects of RapaLink-1 and rapamycin on proliferation and p-RPS6S235/236 and p-4EBP1T37/46, but FK-506 did not block the cellular effects of MLN0128 (Figures 6F and 6G). These results suggest that RapaLink-1 is required for the activity of RapaLink-1.

To directly compare the binding of rapamycin-FKBP-2 and RapaLink-1-FKBP12 with mTORC1, we immunoprecipitated mTOR and used western blot analysis for bound FKBP12. Levels of the RapaLink-1-FKBP12 complex bound to mTOR were higher than those of the rapamycin-FKBP2 complex, as shown by increased levels of FKBP12 seen in RapaLink-1-treated cells, compared with rapamycin-treated cells (Figure 6H). The increased affinity of RapaLink-1 for FKBP2 could, in part, underlie our earlier observations that RapaLink-1 is more effective than rapamycin at suppressing mTORC1 activity and proliferation.

**DISCUSSION**

Earlier-generation inhibitors of mTOR have limited activity in GBM tumors both preclinically and clinically. It is well-established that rapamycin and other allosteric inhibitors of mTORC1 are potent inhibitors of the mTORC1 target S6K, whereas these agents are relatively inefficient inhibitors of 4EBP1 (reviewed in Baretic and Williams, 2014). TORK1 have better anti-proliferative properties than allosteric inhibitors. Although improved activity was anticipated based on the ability of orthosteric inhibitors to block mTORC2, the increased efficacy of TORK1 was ultimately traced to better inhibition of mTORC1. Specifically, TORK1 more effectively block 4EBP1 compared with rapamycin (Feldman et al., 2009; Garcia-Martinez et al., 2009; Thoreen et al., 2009).

As expected, our in vitro studies showed that the clinical TORK1 MLN0128 was more effective than rapamycin in cell culture, correlating with improved inhibition of the mTORC1 target 4EBP1. Despite this increased activity; however, we show here that MLN0128 shows a short residence time (Bradshaw et al., 2015) and decreased in vivo activity compared with rapamycin. In addition, despite its inability to block 4EBP1 phosphorylation in vitro, rapamycin did show some blockade of this target in vivo. The improved in vivo efficacy of RapaLink-1 compared with earlier-generation inhibitors of mTOR is likely due both to its
Figure 5. RapaLink-1 Accumulates in Cells, Durably Blocking mTORC1

(A) U87MG cells were treated with 200 nM MLN0128, 1.56 nM RapaLink-1, or 10 nM rapamycin for 24 hr. Cells were resuspended in medium without inhibitors and grown for the amounts of time indicated (0–4 days). Proliferation was measured by WST-1 assay. Data shown are mean ± SD (percentage growth relative to DMSO-treated control) of triplicate measurements.

(B) Cells were treated as in (A) for 24 hr. Cells were resuspended in medium without inhibitors, grown for times indicated (1–48 hr), harvested, lysed, and analyzed by western blotting as indicated. Representative blots from three independent experiments are shown.

(C) U87MG cells were treated with DMSO or 1.56 nM RapaLink-1 for 24 hr (left two lanes). Cells treated with RapaLink-1 were resuspended in medium with or without 1 μM FK-506 in the absence of RapaLink-1 for 1–4 days (right three lanes). Proliferation was measured by WST-1 assay, n.s., not significant; day 2, RapaLink-1 washout versus RapaLink-1 washout + FK-506, p = 0.08; day 4, RapaLink-1 washout versus RapaLink-1 washout + FK-506, ***p < 0.0001. Data shown represent mean ± SD (percentage growth relative to DMSO-treated control) of triplicate measurements. The C group represents DMSO treatment alone.

(D) U87MG cells were treated with DMSO, 1 μM FK-506, or 1.56 nM RapaLink-1 for 24 hr (left three lanes). Cells treated with RapaLink-1 for 24 hr were resuspended in medium with 1 μM FK-506 in the absence of RapaLink-1, and grown for 1–48 hr (right 5 lanes). Cells were harvested, lysed, and analyzed by western blotting as indicated. Representative blots from two independent experiments are shown. The C group represents DMSO treatment alone.

(E) LN229:EGFRvIII and U87MG:EGFRvIII cells were treated with 1.56 nM RapaLink-1 for the times indicated. Proliferation was measured by WST-1 assay. Data shown are mean ± SD (percentage growth relative to DMSO-treated control) of triplicate measurements.

(F) Cells treated as in (E) were harvested, lysed, and analyzed by western blotting as indicated.

(G) Apoptotic cells treated as in (E) were analyzed by flow cytometry for Annexin V. Cells treated with 1 μM staurosporine (STS) for 24 hr were used as a positive control. Data shown represent mean ± SD (fold change compared with RapaLink-1 0 hr treatment) of triplicate measurements. An aliquot of cells was analyzed by western blotting as indicated (bottom panel). See also Figure S4.
hygromycin (500 µg/mL) and that block emergent resistance would help to position resistance, and to identify combinations that promote apoptosis to establish the basis for recurrence, such as induction of auto-
fected and transduced cells were selected as pools with G418 (800 µg/mL) (Fan et al., 2007), the packaging cell line 293T was co-transfected with 
generate retrovirus to transduce LN229 and U87MG with EGFR or EGFRvIII stably into LN229 cells using Effectene Transfection Reagent (QIAGEN). To 
collected at 48 hr and used to infect cells as described (Fan et al., 2006). Trans-
porters as monotherapies are not sufficient to achieve anti-tumor efficacy. Despite its size, RapaLink-1 crossed the blood-brain barrier and could induce regression in orthotopic xenograft, PDX, and genetically engineered models for brain cancer. This class of agents thus holds promise for future therapy of patients with GBM.

While RapaLink-1 promoted regression in GBM models, this initial regression was followed by regrowth of the tumor. Such recurrence is consistent with data suggesting that mTOR inhibitors as monotherapies are not sufficient to achieve anti-tumor responses in most cancers (Ilagan and Manning, 2016). Studies to establish the basis for recurrence, such as induction of autophagy, feedback loops, rewiring, or other modes of acquired resistance, and to identify combinations that promote apoptosis and that block emergent resistance would help to position RapaLink-1 for clinical development.

**EXPERIMENTAL PROCEDURES**

**Cell Lines, Reagents, Transfection, and Transduction**

Human glioma cell lines were grown in 10% fetal bovine serum. These included LN229, U87MG, GBM43, GBM5, and GBM12 (Sarkaria et al., 2006), Plasmids pcDNA3-mTOR WT, pcDNA3-mTOR R2448P, pcDNA3-mTOR S2215V (Sato et al., 2010) were obtained from Addgene (plasmid nos. 26036–8); and transected stably into LN229 cells using Effectene Transfection Reagent (Qiagen). To generate retrovirus to transduce LN229 and U87MG with EGFR or EGFRvIII (Fan et al., 2007), the packaging cell line 293T was co-transfected with pWLZ-hygro-EGFR plasmid gag/pol and VSVg or with pLRNL-neo-EGFRvIII protein S235/236, S6 ribosomal protein, p-4EBP1 T37/46, and 4EBP1 (Cell 

**Western Blotting**

Membranes were blotted with p-AKTT308, p-AKT S473, AKT, p-NDRG1 T346, NDRG1, p-S6K1 S240/244, p-S6K1 T389, SGK1, p-S6K1 T347, SGK3, p-S6 ribosomal protein S235/236, S6 ribosomal protein, p-4EBP1 T37/46, and 4EBP1 (Cell Signaling Technology), p-EGFR Y1173, FKBP12 (Novus Biologicals), EGFR, mTOR, normal mouse immunoglobulin G (IgG) (Santa Cruz Biotechnology), GAPDH, and β-tubulin (Upstate Biotechnology). Bound antibodies were detected with horseradish peroxidase-linked anti-mouse or anti-rabbit IgG (Calbiochem), followed by ECL (Amersham).

**Cell Proliferation Assays, Apoptosis Detection, and Flow Cytometry**

For proliferation, 5 × 10^4 cells were seeded in 12-well plates and treated as indicated for 3 days. Proliferation was determined by WST-1 absorbance (Roche), read at 40 min. For flow cytometry, 5 × 10^5 cells were seeded in six-well plates and treated as indicated for 24 hr. Cells were harvested and fixed in 70% ethanol for 30 min, stained with 5 µg/mL propidium iodide containing 125 unit/mL RNase, and filtered through a 35 µm nylon mesh (Corning Life Sciences). Ten thousand stained nuclei were analyzed in a FACSort flow cytometer (Becton Dickinson). DNA histograms were modeled offline using ModFit LT software (Verity Software House). Apoptosis was detected by measurement of SubG1 fraction, by western blotting for cleaved poly(ADP-ribose) polymerase, or by flow cytometry for Annexin V-FITC as per the manufacturer’s protocol (Annexin V-FITC Detection Kit, BioVision Technologies) using FlowJo software (Tree Star).

**PI3K/P4,5P2 Quantification**

PI3P/P4,5P2 levels were measured by ELISA (Echelon K-2505s). In brief, 10^4 cells were seeded in 10 cm plates, treated as indicated for 3 hr, harvested with cold 0.5 M trichloroacetic acid, and centrifuged. Pellets were suspended in 5% trichloroacetic acid/1 µM EDTA, vortexed, and centrifuged. Neutral lipids were extracted in MeOH/CHCl_3 (2:1), vortexed, and centrifuged. Acidic lipids were extracted by adding 2.25 mL MeOH/CHCl_3 12 N HCl (80:40:1), vortexed, and centrifuged. CHCl_3 (0.75 mL) and 0.1 M HCl (1.35 mL) were added to the supernatant. Samples were vortexed and centrifuged, collecting the lower organic phase. Samples were dried, resuspended in 200 µL of PBS-Tween 3% protein stabilizer, and sonicated before adding to the ELISA. Each sample was assayed in triplicate and absorbance (450 nm) read on a plate reader.

**RESULTS**

**Figure 6. FKBP12 Is Required for RapaLink-1 and Rapamycin Activity**

(A) Model: FKBP12 bound to rapamycin or RapaLink-1 can interact with the FRB domain of mTORC1, whereas FKBP12 binding is not required for MLN0128.

(B) LN229 cells were treated with RapaLink-1 alone or in combination with rapamycin at the doses indicated. Proliferation was measured by WST-1 assay after treatment for 3 days. Data shown represent mean ± SD (percentage growth relative to DMSO-treated control) of triplicate measurements. n.s., not significant.

(C) LN229 and U87MG cells were pre-treated with FK-506 for 30 min and then treated with mTOR inhibitors alone or with FK-506 at doses indicated for 3 days. Cell proliferation was measured by WST-1 assay. Data shown are mean ± SD (percentage growth relative to DMSO-treated control) of triplicate measurements. n.s., not significant.

(D) LN229 and U87MG cells were pre-treated with FK-506 for 30 min and then treated with mTOR inhibitors alone or with FK-506 at doses indicated for 3 days. Cell proliferation was measured by WST-1 assay after treatment for 3 days. Data shown are mean ± SD (percentage growth relative to DMSO-treated control) of triplicate measurements.

(E) Cells treated as in (D) for 3 hr were harvested, lysed, and analyzed by western blotting as indicated. Cell lysates were from a single experiment. Gels were run for the same period of time, and blots were processed with equivalent exposure times, to assure reproducibility. Representative blots from two independent experiments are shown.

(F) LN229 and U87MG cells were pre-treated with FK-506 for 30 min and then treated with mTOR inhibitors alone or with FK-506 at doses indicated for 3 days. Cell proliferation was measured by WST-1 assay. Data shown are mean ± SD (percentage growth relative to DMSO-treated control) of triplicate measurements. n.s., not significant.

(G) Cells treated as in (F) for 3 hr were harvested, lysed, and analyzed by western blotting as indicated. Representative blots from two independent experiments are shown.

(H) LN229 and U87MG cells were treated with inhibitors as indicated for 24 hr. mTOR was immunoprecipitated using a mouse monoclonal mTOR antibody, and immunoprecipitates (IP) were analyzed by western blotting (WB) to detect FKBP12. Mouse IgG was used as negative control. Whole-cell lysates blotted with mTOR, FKBP12, and GAPDH antibodies served as input controls. Representative blots from three independent experiments are shown.
Immunoprecipitation
Protein (200 μg) was incubated with 1 μg anti-mTOR mouse monoclonal anti-body (Santa Cruz Biotechnology) or control mouse IgG at 4°C overnight with gentle agitation. Protein G agarose (40 μL) was added, and samples incubated for 1 hr at 4°C. Immunocomplexes were then pelleted, washed multiple times at 4°C, and subjected to SDS-PAGE and western blotting, using anti-FKBP12 rabbit polyclonal antibody (Cell Signaling Technology).

In Vitro Luciferase Assay and Bioluminescence Imaging
Luciferase-modified GBM43 and GBM5 cells (1 x 10^5) were plated on 24-well plates and treated with MLN0128, RapaLink-1, or rapamycin for 3 days. D-Luciferin was added to a final concentration of 0.6 mg/mL. After 10 min, luminescence was measured on an IVIS Lumina System (Caliper Life Science) with Living Image software. Mice were injected i.p. with 64 mg/kg (U87MG and GBM43) or with 80 mg/kg (GTML) of D-luciferin dissolved in sterile saline. Tu-
mor bioluminescence was determined 20 min after D-luciferin injection, as the sum of photon counts/s in regions of interest, defined by a lower threshold value of 25% of peak pixel intensity. Imaging was performed every 5 days after tumor implantation until the last day on which all mice in all groups were alive.

Immunohistochemical Analyses
Immunohistochemical stains were performed by the UCSF Brain Tumor Research Center Tissue Core. After resection, mouse brains (three per group) were fixed for 12 hr in 4% paraformaldehyde in PBS. Brains were paraffin-embedded, and sectioned (5 μm) for H&E staining and immunohistochemical analyses. Immunostaining was performed using a Benchmark XT automated stainer (Ventana Medical Systems). Sections were immunostained with anti-bodies against Ki67 (mouse monoclonal DAK-H1-WT, Dako, diluted 1:100). Antibodies were detected with the Ventana IVIEW DAB Detection Kit (yielding a brown reaction product). Slides were counterstained with hematoxylin, dehydrated and mounted in DePeX mounting medium (SERVA).

Complete Blood Count and Chemistry Panel Testing
BALB/Cnu/nu mice (three mice each group, Simonsen Laboratories) were treated on day 0 with i.p. injections of vehicle (daily). MLN0128 (1.5 mg/kg, daily), rapamycin (1.5 mg/kg, daily), or RapaLink-1 (1.5 mg/kg, every 5 days) and euthanized on days 1, 3, and 7. Blood samples were collected by cardiac puncture under anesthesia. Blood was collected into EDTA anti-coagulant tubes. Blood counts were measured using a Bio-Rad TC20 automated cell counter. For serum collection, blood was allowed to clot for at least 30 min at room temperature before serum separation by centrifugation at 3,000 g for 15 min. Levels of alanine transaminase, aspartate transaminase, and blood urea nitrogen were measured by IDEXX Laboratories.

In Vivo Studies
All animal experiments were conducted using protocols approved by Univer-
sity of California, San Francisco’s Institutional Animal Care and Use Commit-
tee (IACUC). GTML mouse models were described previously (Swartling et al., 2013). Three 4- to 6-week-old female athymic BALB/Cnu/nu mice were treated with i.p. injections of vehicle (20% DMSO, 40% PEG-300, and 40% PBS [v/v]), MLN0128 (16 mg/kg), RapaLink-1 (0.4 mg/kg), Rapalyn-1 (4 mg/kg), or rapamycin (4 mg/kg) for 15 min, followed by i.p. injection of 250 μL insulin or saline, then killed 15 min later. Skeletal muscle, liver, and brain of each mouse were lysed, and analyzed by western blotting. Orthotopic injections and treatment studies: female BALB/Cnu/nu mice (4 to 6 weeks old) were anesthetized using ketamine and xylazine. U87MG (3 x 10^6) were mixed with Matrigel (1:1). Tumors were implanted in the left parietal lobe of recipient mice. Tumors were treated with U87MG model. A.Y.Q.T. and T.N. performed in vitro experiments with the GTML model. O.A. performed in vivo experiments with the GTML model. J.J.P. analyzed immunohistology. C.J.N. and M.O. provided RapaLink-1. C.J.N., M.O., W.C.G., and D.H.K. analyzed data. Q.W.F. and W.A.W. wrote the manuscript.

Statistical Analysis
Survival analysis was performed using the GraphPad Prism 6 program (GraphPad). significance was determined by the log rank (Mantel-Cox) test. For all other analyses, a two-tailed unpaired Student’s t test was applied.

SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and can be found with this article online at http://dx.doi.org/10.1016/j.ccell.2017.01.014.

AUTHOR CONTRIBUTIONS
Q.W.F., K.M.S., and W.A.W. conceived the project. Q.W.F., R.A.W., S.L., and A.Y.Q.T. performed in vitro experiments and in vivo experiments with the U87MG model. A.Y.Q.T. and T.N. performed in vitro experiments, and Q.W.F., G.C., and E.F.S. performed in vivo experiments with the GBM43 model. O.A. performed in vivo experiments with the GTML model. J.J.P. analyzed immunohistology. C.J.N. and M.O. provided RapaLink-1. C.J.N., M.O., W.C.G., and D.H.K. analyzed data. Q.W.F. and W.A.W. wrote the manuscript.

ACKNOWLEDGMENTS
We thank Francis Burrows, Arman Jahangiri, and Yi Liu for critical review, Pingda Ren and Liansheng Li for small-molecule inhibitors, and David James for GBM5, GBM12, and GBM43. K.M.S. is an inventor on patents related to MLN0128 held by the University of California, San Francisco, and sublicensed to Takeda Pharmaceuti-
cal. M.O. is an employee of, and K.M.S. is a consultant to Takeda Pharmaceuticals Company, Limited, which is conducting MLN0128 clinical trials. Supported by NIH grants R01NS091620, R01NS088688, R01CA148699, R01NS088688, U01CA176278, P30CA82103, U54CA163155, P50AA017072, and Kura Oncology; as well as Children's Tumor, CureSearch, Ross K. MacNeill, and the Samuel Waxman Cancer Research Foundations.

Received: January 26, 2016
Revised: August 19, 2016
Accepted: January 26, 2017
Published: March 13, 2017

REFERENCES


